Mounia Azzi

Biography

Mounia leads NEOMED-LABS’ corporate strategies and development. Prior to joining NEOMED-LABS, she was Director, Scientific Affairs at the NEOMED Institute, responsible for the identification and evaluation of new opportunities to complement NEOMED’s prospecting activities. Before joining the NEOMED initiative, she was Director of Programs at CQDM, where she was responsible for the evaluation and management of research projects and funding programs. Previously, she was Investment Manager at MSBi Valorization, where she covered all aspects of the valorization and investment process, including identification, evaluation, due diligence, negotiation, and fundraising for opportunities in the life sciences sector. She was also actively involved in business development activities with potential industry partners. She started her career as leader of the cellular biology group at Bellus Health (formerly Neurochem Inc.), where she was involved in the development of therapeutics targeting Alzheimer’s disease and diabetes. Mounia holds a PhD degree in Neuroscience from Université Pierre et Marie Curie (UPMC) in Paris.

Research Interest

Mounia leads NEOMED-LABS’ corporate strategies and development. Prior to joining NEOMED-LABS, she was Director, Scientific Affairs at the NEOMED Institute, responsible for the identification and evaluation of new opportunities to complement NEOMED’s prospecting activities. Before joining the NEOMED initiative, she was Director of Programs at CQDM, where she was responsible for the evaluation and management of research projects and funding programs. Previously, she was Investment Manager at MSBi Valorization, where she covered all aspects of the valorization and investment process, including identification, evaluation, due diligence, negotiation, and fundraising for opportunities in the life sciences sector. She was also actively involved in business development activities with potential industry partners. She started her career as leader of the cellular biology group at Bellus Health (formerly Neurochem Inc.), where she was involved in the development of therapeutics targeting Alzheimer’s disease and diabetes. Mounia holds a PhD degree in Neuroscience from Université Pierre et Marie Curie (UPMC) in Paris.